CNTX

Context Therapeutics Inc

Add to Watchlist

Advanced Chart

0.781

+0.008(+1.030%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

0.8044

Open

0.770

VWAP

0.79

Vol

42.38K

Mkt Cap

70.06M

Low

0.750

Amount

33.41K

EV/EBITDA(TTM)

Total Shares

75.00M

-19.29M

EV/OCF(TTM)

P/S(TTM)

Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.

5 Analyst Rating

492.83% Upside

Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.63 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

492.83% Upside

Current: 0.781

Low

4.00

Averages

4.63

High

5.00

492.83% Upside

Current: 0.781

Low

4.00

Averages

4.63

High

5.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-05-08

New

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-05-08

New

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-29

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-29

Maintains

Strong Buy

Reason

William Blair

Matt Phipps

Buy

Initiates

n/a

2025-04-21

Reason

William Blair

Matt Phipps

Price Target

n/a

2025-04-21

Initiates

Buy

Reason

William Blair initiated coverage of Context Therapeutics with an Outperform rating. The biopharmaceutical industry is entering a phase of significant advancements in the development of T-cell engagers for solid tumors and Context stands to benefit from the knowledge gained by the field in developing its three wholly owned programs, the analyst tells investors in a research note. The firm believes Claudin 6 is an ideal target for CD3-based TCEs, given the limited expression on healthy tissues. Blair thinks the readout of initial results in 2026 will be a "significant inflection point for Context shares given the significant potential of this asset alone."

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-09

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-09

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-03-21

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-03-21

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Context Therapeutics Inc (CNTX.O) is -2.86, compared to its 5-year average forward P/E of -2.82. For a more detailed relative valuation and DCF analysis to assess Context Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.82

Current PE

-2.86

Overvalued PE

-0.37

Undervalued PE

-5.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.35

Undervalued EV/EBITDA

-1.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00